• Profile
Close

Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: A randomized controlled trial

Obstetrics and Gynecology Sep 28, 2018

Zigler RE, et al. - Researchers investigated the efficacy of ulipristal acetate vs placebo in reducing the number of bleeding days in etonogestrel implant users in a 30-day period. As per outcomes, etonogestrel contraceptive implant users found ulipristal acetate to be well-tolerated with a reduced number of bleeding days.

Methods

  • Researchers undertook a single-center, randomized, double-blind, placebo-controlled trial.
  • Women aged 18–45 years with an etonogestrel implant in place for greater than 90 days and less than 3 years who reported greater than one bleeding episode in a 24-day period were eligible for participation.
  • They provided 15 mg ulipristal acetate to enrolled participants compared with an identical-appearing placebo daily for 7 days.
  • Using automated text messaging, participants completed daily bleeding diaries to evaluate whether ulipristal acetate reduces the number of bleeding days as compared with placebo.
  • Participant satisfaction with bleeding and the effect of ulipristal acetate on ovulation status were assessed as the secondary outcomes.
  • They planned a sample size of 52 per group (n=104), calculated with an effect size of a 30% reduction in bleeding days, SD of 10 days, and dropout of 15%.
  • They evaluated the effect of ulipristal acetate on ovulatory potential in a subset with weekly serum progesterone.

Results

  • Researchers allocated 65 women to receive 15 mg ulipristal acetate (n=32) or placebo (n=33) daily for 7 days from May 2017 to January 2018.
  • The groups were similar regarding demographic characteristics.
  • Findings revealed 5 fewer days of bleeding over a 30-day reference period after treatment among women receiving ulipristal acetate (P=.002).
  • Women in the ulipristal acetate group vs the placebo group were more satisfied with their bleeding profile at the end of the 30-day follow-up period (87.5% vs 60%, respectively; P < .001).
  • In a subset of each group, serum progesterone levels were nonovulatory (placebo group range: less than 0.2–1.3 ng/mL; ulipristal acetate group range: less than 0.2–4.4 ng/mL).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay